Clinical experience with denosumab discontinuation
Authors' conclusion
Adhering to the recommendation in the ECTS position statement, a mean of 3 infusions of ZOL limited the bone loss 12 and 24 months after DMAb discontinuation, thereby preserving most of the BMD gained during DMAb treatment.
Study context
- Population
- Women and men referred for denosumab discontinuation after a mean treatment duration of 6.7 ± 2.7 years44 with 12-month BMD
- Participants
- 66 women
- Outcome
- Change in BMD 12 months after initial ZOL
- Follow-up
- 12 months
Methodological detailsbased on medical records
- Based on medical records
Main finding
As reported in the abstract
LS BMD decrease (mean ± SD), p ≤ 0.001
2.5 ± 4.2%
TH BMD decrease (mean ± SD), p ≤ 0.001
1.9 ± 2.5%
FNBMD change, no significant change (p > 0.05)
0.0 ± 5.1
Observational data: associations, not effects.
Further findings
Change in BMD from month 12 to month 24
- No significant change in BMD at any site (p > 0.05 for all)
Safety
Flu-like symptoms after zoledronate (ZOL) infusion
- After first ZOL infusion
- 30%
- After second ZOL infusion
- 22%
Fractures · study period
- No fractures occurred
Original publication
Clinical experience with denosumab discontinuation. Osteoporos Int. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →